{"analyses":[{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1320","pValueComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.78","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Value is NA due to an insufficient number of participants with the event.","groupId":"OG000","lowerLimit":"62.3","upperLimit":"NA","value":"81.1"},{"groupId":"OG001","lowerLimit":"34.6","upperLimit":"75.6","value":"54.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"},{"description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Crizotinib"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From randomization until death (up to 10.5 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}